22157.jpg
Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024: Deals Listed by Company A-Z, Headline Value, Therapeutic Area, and Technology Type
March 08, 2024 07:44 ET | Research and Markets
Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering.Joint Venture Deals in...
BredisHealthcare_logo_hori.png
Bredis Healthcare Awarded South Korean Government Grant for Advancing Early Diagnosis of Alzheimer's Disease
August 22, 2023 02:45 ET | Bredis Healthcare Inc.
Bredis Healthcare secures KRW 1.7 billion grant for advancing Alzheimer’s disease diagnosis from South Korean government’s Deep Tech TIPS programNovel platform has demonstrated detection of...
22157.jpg
Global Bioelectronic Medicine Market Analysis, 2018-2028 - Rising Demand for Advanced Healthcare Products
June 28, 2023 04:53 ET | Research and Markets
Dublin, June 28, 2023 (GLOBE NEWSWIRE) -- The Global Bioelectronic Medicine Markets, 2018-2028 report has been added to ResearchAndMarkets.com's offering.The global bioelectronic medicine market is...
Global Printed Electronics Market
$19+ Billion Worldwide Printed Electronics Industry to 2031 - Increasing Demand from the Automotive Industry Drives Growth
January 20, 2023 04:03 ET | Research and Markets
Dublin, Jan. 20, 2023 (GLOBE NEWSWIRE) -- The "Printed Electronics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
NeuroSigma.png
NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
June 14, 2022 11:00 ET | NeuroSigma, Inc.
Double-blind randomized controlled trial will enroll up to 225 children at UCLA and Seattle Children’s Hospital NeuroSigma will provide Monarch eTNS Systems and funding for long-term follow-up ...
NeuroSigma.png
NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®
February 22, 2022 11:00 ET | NeuroSigma, Inc.
LOS ANGELES, Feb. 22, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced FDA Breakthrough Device Designation for its Monarch eTNS System® for...
NeuroSigma.png
NeuroSigma Announces Promotion of Dr. Colin Kealey to President
January 11, 2022 11:00 ET | NeuroSigma, Inc.
LOS ANGELES, Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion of Dr. Colin Kealey to President. NeuroSigma is the developer...
Signing Ceremony
NeuroSigma Announces a $5 Million Equity Investment by KT Corporation
December 08, 2021 05:00 ET | NeuroSigma, Inc.
Transaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KTSignificant investment in NeuroSigma’s digital health and neuro-electronics platform ...
EMED Logo.png
Electromedical Technologies and Nazarbayev University to Commence Landmark Alzheimer's Disease Research Program
July 29, 2021 06:00 ET | Electromedical Technologies, Inc.
SCOTTSDALE, AZ, July 29, 2021 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and production of bioelectronic devices designed to...
22157.jpg
Global Biohacking Market (2020 to 2027) - Share, Size, Trends, Industry Analysis Report
March 04, 2021 06:18 ET | Research and Markets
Dublin, March 04, 2021 (GLOBE NEWSWIRE) -- The "Biohacking Market Share, Size, Trends, Industry Analysis Report, By Type; By Product; By Application; By End Use; By Regions; Segment Forecast,...